Molbrick is a start-up developing novel antimicrobial agents to treat drug-resistant mycobacteria. It has designed small-molecule target cellular compartments that are essential for DNA replication. Molbrick's platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.